MSH6

Across TCGA pan-cancer cohorts, MSH6 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MSH6’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MSH6 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MSH6 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, COAD, and LUAD are the cancer types where MSH6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MSH6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.491	<.001	12	view →
COAD	Male	III,IV	+0.614	<.001	11	view →
LUAD	Male	All	+0.652	<.001	9	view →
LSCC	Male	All	+1.189	<.001	8	view →
HNSC	Male	IV	+0.699	<.001	8	view →
PDAC	Female	All	−0.226	.001	4	view →
OV	All	All	+0.460	.031	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MSH6–CCRCC

Open the CCRCC breakdown →